Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Mattsson

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Current Topics in Medicinal Chemistry|September 24, 2005
Recent advances in non-competitive mGlu5 receptor antagonists and their potential therapeutic applicationsAbdelmalik Slassi, Methvin Isaac, Louise Edwards, et al.
Oncotarget|September 18, 2014
Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisionsBerglind O Einarsdottir, Roger Olofsson Bagge, Joydeep Bhadury, et al.
Cancer|May 7, 2003
The Gothenburg Breast Screening TrialNils Bjurstam, Lena Björneld, Jane Warwick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2023
Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial)Roger Olofsson Bagge, Axel Nelson, Amir Shafazand, et al.
Annals of Surgery|February 29, 2024
Survival and Quality of Life After Isolated Hepatic Perfusion With Melphalan as a Treatment for Uveal Melanoma Liver Metastases: Final Results From the Phase III Randomized Controlled Trial SCANDIUMRoger Olofsson Bagge, Axel Nelson, Amir Shafazand, et al.
Cancers|June 24, 2022
Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage I-II Melanoma Patients at Risk of Disease RelapseEvalyn E A P Mulder, Iva Johansson, Dirk J Grünhagen, et al.
European Journal of Cancer (Oxford, England : 1990)|July 15, 2023
Variation in response rates to isolated limb perfusion in different soft-tissue tumour subtypes: an international multi-centre studySophie J M Reijers, Emma Davies, Dirk J Grünhagen, et al.
Journal for Immunotherapy of Cancer|August 24, 2022
Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissectionZeynep Eroglu, Kristy K Broman, John F Thompson, et al.
Journal of the American College of Surgeons|December 14, 2020
Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched AnalysisKristy K Broman, Tasha M Hughes, Lesly A Dossett, et al.
Cancer|April 7, 2021
Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2)Kristy Kummerow Broman, Tasha Hughes, Lesly Dossett, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Current Topics in Medicinal Chemistry|September 24, 2005
Recent advances in non-competitive mGlu5 receptor antagonists and their potential therapeutic applicationsAbdelmalik Slassi, Methvin Isaac, Louise Edwards, et al.
Oncotarget|September 18, 2014
Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisionsBerglind O Einarsdottir, Roger Olofsson Bagge, Joydeep Bhadury, et al.
Cancer|May 7, 2003
The Gothenburg Breast Screening TrialNils Bjurstam, Lena Björneld, Jane Warwick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2023
Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial)Roger Olofsson Bagge, Axel Nelson, Amir Shafazand, et al.
Annals of Surgery|February 29, 2024
Survival and Quality of Life After Isolated Hepatic Perfusion With Melphalan as a Treatment for Uveal Melanoma Liver Metastases: Final Results From the Phase III Randomized Controlled Trial SCANDIUMRoger Olofsson Bagge, Axel Nelson, Amir Shafazand, et al.
Cancers|June 24, 2022
Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage I-II Melanoma Patients at Risk of Disease RelapseEvalyn E A P Mulder, Iva Johansson, Dirk J Grünhagen, et al.
European Journal of Cancer (Oxford, England : 1990)|July 15, 2023
Variation in response rates to isolated limb perfusion in different soft-tissue tumour subtypes: an international multi-centre studySophie J M Reijers, Emma Davies, Dirk J Grünhagen, et al.
Journal for Immunotherapy of Cancer|August 24, 2022
Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissectionZeynep Eroglu, Kristy K Broman, John F Thompson, et al.
Journal of the American College of Surgeons|December 14, 2020
Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched AnalysisKristy K Broman, Tasha M Hughes, Lesly A Dossett, et al.
Cancer|April 7, 2021
Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2)Kristy Kummerow Broman, Tasha Hughes, Lesly Dossett, et al.
Pageof 4